Implementing biomarkers and clinical probes to assess transporter-mediated drug-drug interactions | An ISSX 2025 Short Course

Implementing biomarkers and clinical probes to assess transporter-mediated drug-drug interactions | An ISSX 2025 Short Course

  • Register
    • Non-member - $300
    • Member - $200
    • Student - $75
    • Premier - Free!

    Continue

Co-Chairs: Bhagwat Prasad, Cincinnati Children’s Hospital, USA and Eva Berglund, Certara, USA

  • Strengths and weaknesses of biomarker PBPK models to assess transporter-mediated DDIs
    Hiroyuki Kusuhara, The University of Tokyo, Japan
  • Endogenous Probes in Practice: Why, When, and How?
    Ryota Kikuchi, AbbVie, USA
  • Clinical transporter probes: Selectivity and sensitivity
    Xiaoyan Chu, Merck, USA
  • Endogenous transporter probes from a regulatory perspective
    Xinning Yang, Ellicott City, MD, USA

Key:

Complete
Failed
Available
Locked
SC 2.1 Strengths and weaknesses of biomarker PBPK models to assess transporter-mediated DDIs | Hiroyuki Kusuhara, The University of Tokyo, Japan
Open to view video.
Open to view video. This short course covers the design, purpose, and regulatory expectations of human radiolabeled mass balance studies, emphasizing their role in understanding drug disposition, informing drug development decisions, and supporting DDI assessments and PBPK modeling.
You must register to access.
SC 2.2 Endogenous Probes in Practice: Why, When, and How? | Ryota Kikuchi, PhD, AbbVie, USA
Open to view video.
Open to view video. This short course covers the design, purpose, and regulatory expectations of human radiolabeled mass balance studies, emphasizing their role in understanding drug disposition, informing drug development decisions, and supporting DDI assessments and PBPK modeling.
You must register to access.
SC 2.3 Clinical transporter probes: Selectivity and sensitivity​ | Xiaoyan Chu, Merck, USA
Open to view video.
Open to view video. This short course covers the design, purpose, and regulatory expectations of human radiolabeled mass balance studies, emphasizing their role in understanding drug disposition, informing drug development decisions, and supporting DDI assessments and PBPK modeling.
You must register to access.
SC 2.4 Endogenous transporter probes from a regulatory perspective | Xinning Yang, Ellicott City, MD, USA
Open to view video.
Open to view video. This short course covers the design, purpose, and regulatory expectations of human radiolabeled mass balance studies, emphasizing their role in understanding drug disposition, informing drug development decisions, and supporting DDI assessments and PBPK modeling.
You must register to access.
Certificate
No credits available  |  Certificate available
No credits available  |  Certificate available Certificate of Completion
You must register to access.